Skip to main content
SpringerLink
Log in

Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours

  • Original Article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

The aim of this study was to compare, in breast cancer patients, the diagnostic accuracy of positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) and scintimammography (SMM) using technetium-99m methoxyisobutylisonitrile (MIBI). A total of 20 patients (40 breasts with 22 lesions) were evaluated serially with MIBI and, on the following day, with FDG. For SMM, planar and single-photon emission tomography imaging in the prone position was performed starting at 10 min following the injection of MIBI (740 MBq). For PET, scans were acquired 45–60 min after the injection of FDG (370 MBq) and attentuation correction was performed following transmission scans. Results from SMM and PET were subsequently compared with the histopathology results. True-positive results were obtained in 12/13 primary breast cancers (mean diameter=29 mm, range 8–53 mm) with both FDG and MIBI. False-negative results were obtained in two local recurrences (diameter <9 mm) with both FDG and MIBI. In benign disease, FDG and MIBI did not localize three fibrocystic lesions, two fibroadenomas and one inflammatory lesion (true-negative), but both localized one fibroadenoma (false-positive). Collectively, the results demonstrate a sensitivity of 92%, and a specificity of 86%, for primary breast cancer regardless of whether FDG or MIBI was used. In contrast to MIBI scintigraphy, FDG PET scored the axillae correctly as either positive (metastatic disease) or negative (no axillary disease) in all 12 patients. The tumour/non-tumour ratio for MIBI was 1.97 (range 1.43–3.1). The mean standard uptake value (SUV) for FDG uptake was 2.57 (range 0.3–6.2). The diagnostic accuracy of SMM was equivalent to that of FDG PET for the detection of primary breast cancer. For the detection of in situ lymph node metastases of the axilla, FDG seems to be more sensitive than99mTc-MIBI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kelsey JL, Gammon MD. The epidemiology of breast cancer.Cancer 1991; 41: 146–165.

    Google Scholar 

  2. Berg JW, Hutter RV. Breast cancer.Cancer 1995; 75: 257–269.

    PubMed  Google Scholar 

  3. Sondik EJ. Breast cancer trends. Incidence, mortality and survival.Cancer 1994; 74: 995–999.

    PubMed  Google Scholar 

  4. Andersson I. Mammographic screening and mortality from breast cancer: Malmö mammographic screening trial.Br J Med 1988; 297: 943–948.

    Google Scholar 

  5. Frisell J, Eklund G, Hellström L, et al. Randomized study of mammography screening — preliminary report on mortality in the Stockholm trial.Breast Cancer Res Treat 1991; 18: 49–56.

    PubMed  Google Scholar 

  6. Miller AB, Baines CJ, To T, et al. Canada national breast screening study.Can Med Assoc J 1992; 147: 1459–1488.

    Google Scholar 

  7. Kopans DB. The positive predictive value of mammography.AJR 1992; 158: 521–526.

    PubMed  Google Scholar 

  8. Wahl RL, Cody RL, Hutchins GD, Kuhl DE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET imaging of breast cancer with 18FDG.Radiology 1989; 173: 419.

    PubMed  Google Scholar 

  9. Kubota K, Matsuzawa T, Amemiya A, Kondo M, Fujiwara T, Watanuki S, Ito M, Ido T. Imaging of breast cancer with FDG and positron emission tomography.J Comput Assist Tomogr 1989; 13: 1097–1098.

    PubMed  Google Scholar 

  10. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue F-18 fluoro-2-deoxy-d-glucose.Radiology 1991; 179: 765–770.

    PubMed  Google Scholar 

  11. Hoh CK, Hawkins RH, Glaspy JA, Dahlbom M, Tse NY, Hoffmann EJ, Schiepers C, Choi Y, Rege S, Nitzsche E. Cancer detection with whole body PET using18F-deoxyglucose.J Comput Assist Tomogr 1993; 17: 582–589.

    PubMed  Google Scholar 

  12. Tse NY, Hoh CK, Hawkins RH, Zinner MJ, Dahlbom M, Choi Y, Maddahi J, Brunicardi FC, Phelps ME, Glaspy JA. The application of positron emission tomographic imaging with FDG to the evaluation of breast disease.Ann Surg 1992; 216: 27–34.

    PubMed  Google Scholar 

  13. Nieweg OE, Kim EE, Wong WH, Broussard WE, Singletary SE, Hortobagyi GN, Tilbury RS. Positron emission tomography with FDG in the detection and staging of breast cancer.Cancer 1993; 71: 3920–3925.

    PubMed  Google Scholar 

  14. Adler LP, Crowe JP, Al Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with F-18 deoxy-2-fluoro-d-glucose PET.Radiology 1993; 187: 743–750.

    PubMed  Google Scholar 

  15. Jacobs M, Mantil J, Peterson C, Reiling R, Glaser R, Satter M, Nickerson J, Dunigan K, Brackney M. FDG PET in breast cancer [abstract].J Nucl Med 1994; 35: 142.

    Google Scholar 

  16. Avril N, Jänicke F, Dose J, Bense S, Ziegler S, Zinke M, Laubenbacher C, Römer W, Herz M, Schwaiger M. PET imaging of breast tumors: Munich experience [abstract].J Nucl Med 1995; 36: 82.

    Google Scholar 

  17. Dehdashti F, Mortimer JE, Griffeth LK, McGuire AH, Radford DM, Fusselman MJ, Burney RJ, Bonasera TA, Siegel BA, Katzenellenbogen JA, Welch MJ. Positron tomographic assessment of breast lesions with FDG and FES [abstract].J Nucl Med 1994; 35: 141.

    PubMed  Google Scholar 

  18. Kao CH, Wang SJ, Liu TJ. The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses.Eur J Nucl Med 1994; 21: 432–436.

    PubMed  Google Scholar 

  19. Khalkhali I, Mena I, Jouanne E, et al. Prone scintimammography in patients with suspicion of breast cancer.J Am Coll Surg 1994; 178: 491–497.

    PubMed  Google Scholar 

  20. Khalkhali I, Cutrone JA, Mena I. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma.Radiology 1995; 196: 421–426.

    PubMed  Google Scholar 

  21. Palmedo H, Schomburg A, Gruenwald F, Mallman P, Krebs D, Biersack HJ. Scintimammography with Tc-99m MIBI in suspicious breast lesions.J Nucl Med 1996; 37: 626–630.

    PubMed  Google Scholar 

  22. Taillefer R, Robidoux A, Lambert R, Turpin S, Lamperrière J. Tc-99m sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement.J Nucl Med 1995; 36: 1758–1765.

    PubMed  Google Scholar 

  23. Lee V, Sax EJ, McAneny DB, Pollack S, Blanchard RA, Beazley RM, Kavanah MT, Ward RJ. A complementary role for thallium-201 scintigraphy with mammography in the diagnosis of breast cancer.J Nucl Med 1993; 34: 2095–2100.

    PubMed  Google Scholar 

  24. Waxman AD, Ramanna L, Memsic LD, Foster CE, Silberman AW, Gleischmann SH, Brenner RJ, Brachman MB, Kuhar CJ, Yadegar J. Thallium scintigraphy in the evaluation of mass abnormalities of the breast.J Nucl Med 1993; 34: 18–23.

    PubMed  Google Scholar 

  25. Mansi L, Rambaldi PF, Procaccini E, et al. Scintimammography with Tc-99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases.Eur J Nucl Med 1996; 23: 932–939.

    PubMed  Google Scholar 

  26. Crowe JP, Adler LP, Shenk RR, Sunshine J. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings.Ann Surg Oncol 1994; 1: 132–140.

    PubMed  Google Scholar 

  27. Khalkhali I, Mena I, Diggles L. Limitations of mammography: the role of Tc-99m sestamibi scintimammography in the diagnosis of breast cancer [abstract].Clin Nucl Med 1993; 18: 927.

    Google Scholar 

  28. Khalkhali I, Cutrone JA, Mena I, Diggles L, Khalkhali S, Venegas R, Klein S. The usefulness of scintimammography (SMM) in patients with dense breasts on mammogram [abstract].J Nucl Med 1995; 36: 52.

    Google Scholar 

  29. Palmedo H, Grünwald F, Bender H, Schomburg A, Mallmann P, Krebs D, Biersack HJ. Scintimammography with technetium-99m methoxyisobutylisonitrile: comparison with mammography and magnetic resonance imaging.Eur J Nucl Med 1996; 23: 940–946.

    PubMed  Google Scholar 

  30. Lannin DR, Harris RP, Swanson FH, Edwards MS, Swanson MS, Pories WJ. Difficulties in diagnosis of carcinoma of the breast in patients less than fifty years of age.Surg Gynecol Obstet 1993; 177: 123–126.

    Google Scholar 

  31. Coneney EC, Geraghty JG, O'Laoide R, Hourihane JB, O'Higgins NJ. Reasons underlying negative mammography in patients with palpable breast cancer.Clin Radiol 1994; 49: 123–125.

    PubMed  Google Scholar 

  32. Khalkhali I, Cutrone JA, Mena I, Diggles L, Venegas R, Vargas H, Jackson B, Klein S. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up.J Nucl Med 1995; 36: 1784–1789.

    PubMed  Google Scholar 

  33. Tilling R, Kress K, Pechmann M, Pfluger T, Knesewitsch P, Tatsch K, Hahn K. Integrated diagnosis of breast tumors: semiquantitative Tc-99m sestamibi imaging versus dynamic MRI [abstract].J Nucl Med 1995; 35: 51.

    Google Scholar 

  34. Diggles L, Mena I, Khalkhali I. Bilateral increased uptake of Tc-99m sestamibi in scintimammography: its correlation with the menstrual cycle [abstract].J Nucl Med Technol 1994; 22: 111.

    Google Scholar 

  35. Wahl RL, Zasadny KR, Cody R, Helvie M. FDG accumulation in normal breasts declines with aging [abstract].J Nucl Med 1994; 35: 142.

    Google Scholar 

  36. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis 2-methoxyisobutylisonitrile technetium in cultured mouse fibroblasts.J Nucl Med 1990; 1646–1653.

  37. Maublant JC, Zhang Z, Rapp M, Ollier M, Michelot J, Veyre A. In vitro uptake of technetium-99m teboroxime in carcinoma cell lines and normal cells: comparison with technetium-99m sestamibi and thallium-201.J Nucl Med 1993; 34: 1949–1952.

    PubMed  Google Scholar 

  38. Piwnica-Worms D, Chin ML, Budding M, Kronauge JF, Kramer RA, Crooop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.Cancer Res 1993; 53: 977–984.

    PubMed  Google Scholar 

  39. Bender H, Friedrich E, Zamora PO, Biersack HJ. Detection of multi-drug resistance with Tc-99m sestamibi [abstract].J Nucl Med 1995; 36 (Suppl) 129P.

  40. Ciarmiello A, Del Vecchio S, Potena MI, et al. Technetium-99m-sestamibi efflux and P-glycoprotein expression in human breast carcinoma [abstract].J Nucl Med 1995; 36 (Suppl) 129P.

  41. Maublant J, Songalede JA, Finat-Duclos F, Verrelle P, Veyre A, Younès A. Accumulation of Tc-99m sestamibi in cultured tumor cells decreases when multidrug resistance factor is overexpressed [abstract].J Nucl Med 1994; 35 (Suppl): 219P.

  42. Kubota K, Kubota R, Yamada S. FDG accumulation in tumor tissue.J Nucl Med 1993; 34: 419–421.

    PubMed  Google Scholar 

  43. Hawkins RA, Hoh C, Dahlbom M, et al. PET cancer evaluation with FDG.J Nucl Med 1991; 32: 1555–1558.

    PubMed  Google Scholar 

  44. Weber G. Enzymology of cancer cells.N Engl J Med 1977; 296: 486–493.

    PubMed  Google Scholar 

  45. Avril N, Jänicke F, Dose J, Bense S, Ziegler S, Zinke M, Römer W, Weber W, Herz M, Schwaiger M. PET evaluation of axillary lymph node involvement in breast cancer patients [abstract].J Nucl Med 1995; 35: 82.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University of Bonn, Germany

    H. Palmedo, H. Bender, F. Grünwald, P. Zamora & H. J. Biersack

  2. Department of Gynecology and Obstetrics, University of Bonn, Germany

    P. Mallmann & D. Krebs

Authors
  1. H. Palmedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Bender
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Grünwald
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Mallmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Zamora
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Krebs
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. J. Biersack
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palmedo, H., Bender, H., Grünwald, F. et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med 24, 1138–1145 (1997). https://doi.org/10.1007/BF01254246

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01254246

Key words

Search

Navigation